Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
- 15 November 2005
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 96 (9), 1241-1246
- https://doi.org/10.1111/j.1464-410x.2005.05821.x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)Journal of Clinical Oncology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003
- Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6The Prostate, 2003
- In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17α-hydroxylase/C17,20-lyaseThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Effects of novel 17α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivoThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate CancerJournal of Urology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic CancerJournal of Medicinal Chemistry, 1995
- Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)The Journal of Steroid Biochemistry and Molecular Biology, 1994